Business Wire

CA-ENCHROMA

16.7.2024 13:01:33 CEST | Business Wire | Press release

Share
EnChroma Announces Organizations Can Now Join International Color Blindness Awareness Month™ 2024

EnChroma® — creators of glasses for color blindness — today announced that organizations and businesses can now sign up to support International Color Blindness Awareness Month™ 2024. Every September, hundreds of organizations come together to promote ‘color accessibility’ and inclusion for the one in 12 men (8%) and one in 200 women (.5%) who are color blind; an estimated 13 million in the United States; 30 million in Europe; and 350 million worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716891549/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Depiction of red-green color blind and normal color vision views of colorful buildings in Amsterdam. (Photo: Business Wire)

Anytime in September, hundreds of museums, universities, businesses, libraries, schools, park systems, tourism agencies, philanthropic groups and others will make social media posts, disseminate information, and engage in other activities to educate the public about the prevalence and effects of Color Vision Deficiency (CVD).

“Awareness of just how common color blindness is and how significant its impacts are, still remains low amongst employers, educators, parents and the general public,” said Erik Ritchie, CEO of EnChroma. “From color confusion in the workplace, at school, when enjoying sports and the outdoors, or when simply doing daily activities can be frustrating for those with CVD. This year, we hope even more organizations will support International Color Blindness Awareness Month to both educate and advocate on behalf of the color blind.”

While people with normal color vision see over one million shades of color, the red-green color blind only see an estimated 10% of hues and shades. As a result, colors can appear dull, indistinct and difficult to discern; red can appear brown; green can look tan, gray or yellow; and purple and blue look similar.

Click here to see more images depicting color blindness.

Last year, over 250 organizations around the world used their voices and platforms in support including multinational corporations such as Honeywell Aerospace, Siemens Energy and Faber-Castell; renowned museums such as the Centre Pompidou and the Georgia O’Keeffe Museum; universities such as the University of North Carolina, Boston University and North Carolina State University; state and national parks such as Friends of Kauai Wildlife Refuges and Alaska State Parks; the Atlanta Botanical Garden; nature advocates like the Audubon Nature Institute; and groups such as Travel Oregon, Lions and Kiwanis clubs, and the Boy Scouts of America.

How to Apply

Organizations and businesses can sign up here to commit to making at least one social media post, or undertake any other activity, that promotes color blindness awareness in September, using any of an array of customizable images and templates. Do as little as make one social media post using a customizable template or create your own post(s) with easy-to-use tools. Participating organizations can choose to receive two pairs of EnChroma glasses to give away to color blind students, customers, staff or visitors. The offer to give away EnChroma glasses is not available to individuals.

EnChroma Color Accessibility Program™

EnChroma is the lead advocate for ‘color accessibility,’ helping more than 400 universities, K-12 schools, state and national parks, libraries, museums, tourism departments, attractions and other organizations purchase and loan EnChroma glasses to color blind students and guests. EnChroma donates a pair of glasses for each pair an organization buys to lend to the public or students. The program is also open to employers. Scenic viewers adapted for the color blind are also available and in use by park systems across 25 states.

EnChroma glasses are engineered with special optical filters that help the red-green color blind experience an expanded range of colors more vibrantly and distinctly to make schoolwork that involves color, art, nature and other experiences more ‘color accessible.’ The glasses do not deliver full color vision and results and reaction times vary. EnChroma glasses enhance color for approximately 80% of people with deuteranomalous or protanomalous red-green color blindness who have all three of their color sensing cones. Read this study by UC Davis about the glasses.

About EnChroma

Based in Berkeley, Calif., EnChroma produces leading-edge eyewear for red-green color blindness and low vision, and other solutions for color vision, sold online and through Authorized Retailers worldwide. Invented in 2010, EnChroma’s patented eyewear combines the latest in color perception, neuroscience and lens innovation to improve the lives of people with red-green color vision deficiency around the world. EnChroma received an SBIR grant from the National Institutes of Health (NIH). It earned the 2016 Tibbetts Award from the U.S. Small Business Administration in recognition of the firm’s innovative impact on the human experience through technology, and the 2020 Innovation Award in Life Sciences from the Bay Area’s East Bay Economic Development Alliance. Call 510-497-0048 or visit enchroma.com for more.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240716891549/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release

Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult

BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release

Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,

Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release

Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate

Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release

Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction

L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release

Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye